Completed

Viracept Safety and Effectiveness in AIDS Patients with MAC

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Nelfinavir mesylate

Drug
Who is being recruted

Blood-Borne Infections+22

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
See protocol details

Summary

Principal SponsorAgouron Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on AIDS patients who are undergoing treatment for a specific type of infection called Mycobacterium Avium Complex Disease (MAC). The main goal is to explore if a drug named Viracept can safely and effectively improve the treatment outcomes for these patients. This research is important as it aims to find new ways to manage this opportunistic infection, which often affects individuals with AIDS.

NCT00002170
Principal SponsorAgouron Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesActinomycetales InfectionsBacterial Infections and MycosesBacterial InfectionsCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsMycobacterium InfectionsMycobacterium Infections, NontuberculousOpportunistic InfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsGram-Positive Bacterial InfectionsAcquired Immunodeficiency SyndromeMycobacterium avium-intracellulare InfectionHIV InfectionsAIDS-Related Opportunistic Infections

Criteria

2 inclusion criteria required to participate
HIV infection
New diagnosis of MAC bacteremia and < 7 days of therapy
1 exclusion criteria prevent from participating
Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 5 locations

Univ of California / San Diego Treatment Ctr

San Diego, United StatesOpen Univ of California / San Diego Treatment Ctr in Google Maps

Harbor UCLA Med Ctr

Torrance, United States

Rush Presbyterian - Saint Luke's Med Ctr

Chicago, United States

Boston VA Med Ctr / 151

Boston, United States
Completed5 Study Centers